Huaren Pharmaceutical Co Ltd - Asset Resilience Ratio
Huaren Pharmaceutical Co Ltd (300110) has an Asset Resilience Ratio of 0.10% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Huaren Pharmaceutical Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2019)
This chart shows how Huaren Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 300110 current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Huaren Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Huaren Pharmaceutical Co Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥3.00 Million | 0.1% |
| Total Liquid Assets | CN¥3.00 Million | 0.10% |
Asset Resilience Insights
- Limited Liquidity: Huaren Pharmaceutical Co Ltd maintains only 0.10% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Huaren Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Huaren Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Huaren Pharmaceutical Co Ltd (2017–2019)
The table below shows the annual Asset Resilience Ratio data for Huaren Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 0.11% | CN¥2.85 Million ≈ $417.04K |
CN¥2.71 Billion ≈ $396.60 Million |
-0.28pp |
| 2017-12-31 | 0.38% | CN¥11.11 Million ≈ $1.63 Million |
CN¥2.89 Billion ≈ $422.47 Million |
-- |
About Huaren Pharmaceutical Co Ltd
Huaren Pharmaceutical Co., Ltd. produces and sells non-PVC soft bag infusions in China. It offers doxofylline, levofloxacin hydrochloride, compound potassium hydrogen phosphate, and caffeine citrate, sodium chloride, glucose, glucose sodium potassium, chloride, compound sodium chloride, sodium lactate ringer, compound electrolyte, and sterilized water injections. The company also provides therape… Read more